Latest Conference Articles

Elizabeth Loggers, MD, PhD, discussed the phase 3 DeFi study exploring ovarian toxicity in female patients receiving nirogacestat for the treatment of desmoid tumors.

Xiaolin Zhang, PhD, discusses findings from the phase 2 study exploring a novel oral agent for the treatment of EGFR-mutated non–small cell lung cancer.

A study showed that a treatment regimen called BOVen was safe and effective in producing responses in older patients with mantle cell lymphoma.

The combination of englumafusp alfa and glofitamab showed a BOR of 67.0% and CR rate of 57.0% in second-line settings. In third-line settings, the BOR was 65.7% and the CR rate was 52.8%.

Mariam Eskander, MD, MPH, discussed a study exploring how inequity and social vulnerability factor into clinical trial enrollment.

ATO/ATRA plus idarubicin showed superior 2-year EFS (88% vs 70%) and 5-year EFS (87% vs 55%) compared to ATRA/chemotherapy. The trial indicated lower hematologic toxicity with ATO/ATRA, including reduced rates of thrombocytopenia and neutropenia.

Mina Lobbous, MD, MPH, discusses findings and implications fro a study investigating a new regimen for the treatment of brain metastases in patients with HER2-positive breast cancer.

Acalabrutinib and zanubrutinib showed longer median TTD and TTNT compared to ibrutinib in CLL/SLL patients. Cardiovascular adverse effects were less frequent with acalabrutinib and zanubrutinib than with ibrutinib.

A cohort study of the KarMMa-2 trial discovered durable responses in patients with high-risk multiple myeloma treated with ide-cel.

A study found that glofitamab plus gemcitabine and oxaliplatin significantly improved survival in patients with relapsed/refractory diffuse large B-cell lymphoma who were not eligible for stem cell transplant.

An interim analysis of the phase 2 REGINA trial met predefined statistical criteria and suggests the need for further evaluation of the combination of regorafenib, nivolumab, and short-course radiation therapy in patients with locally advanced rectal cancer.

Switch maintenance therapy with paclitaxel plus ramucirumab consistently prolonged survival regardless of clinical or molecular subgroups in HER2-negative disease controlled, metastatic gastric cancer.

Blinatumomab integration led to high complete response and minimal residual disease-negativity rates, especially in patients over 40 and Philadelphia chromosome-positive cases.

Final analysis from KEYNOTE-585 revealed that event-free survival (EFS) was not significantly improved.

Zanubrutinib treatment resulted in £599,000 cost savings and 3.7 QALY savings compared with acalabrutinib for 1000 hypothetical patients.

Disease duration, thrombotic event history, elevated WBC count, HCT levels, and VAF are key predictors of polycythemia vera progression.

An increased likelihood of response was also observed in patients who received no more than 3 lines of therapy prior to liso-cel in the TRANSCEND CLL 004 trial.

Ravi Parikh, MD, MPP, discusses findings and implications of a study exploring algorithm-based palliative care recommendations.

Nikhil Khushalani, MD, discussed a phase 3 study investigating fianlimab plus cemiplimab vs nivolumab and relatlimab for the treatment of patients with advanced melanoma.

Elizabeth Logers, MD, PhD, discusses the implications of ovarian toxicity on female patients of reproductive age being treated with nirogacestat for desmoid tumors.

David Spigel, MD, discussed the findings and implications from the phase 3 ADRIATIC study of durvalumab in small cell lung cancer presented at the 2024 ASCO Annual Meeting.

New or worsening anemia did not appear to reduce the clinical benefit of ruxolitinib in myelofibrosis patients, and the median overall survival was similar between patients with and without new or worsening anemia.

Andrea Roman, PharmD, BCOP, discusses findings from a study investigating the benefits of remote oncology pharmacists.

Vitaly Margulis, MD, discusses the key takeaways and next steps of the Apa-RP study of apalutamide plus androgen deprivation therapy in patients with high-risk localized prostate cancer.

Vitaly Margulis, MD, reflects on the secondary end points findings and safety data from the Apa-RP study in high-risk localized prostate cancer.

Christopher Moertel, MD, discusses mirdametinib's mechanism of action and the implications of the phase 2b ReNeu trial of the agent in NF1-associated plexiform neurofibroma.

The phase 2 PONALFIL trial evaluating a ponatinib regimen shows promise for long-term survival in adult patients with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia.

Vitaly Margulis, MD, discusses the significance of a 100% biochemical recurrence-free rate at 2 years, and what this means for patients with high-risk localized prostate cancer.

Vitaly Margulis, MD, discusses the Apa-RP study of adjuvant treatment consisting of apalutamide and androgen deprivation therapy in patients with high-risk localized prostate cancer.

Zanubrutinib plus venetoclax achieved a 100% overall response rate in patients with treatment-naive CLL/SLL harboring 17p deletions and/or TP53 mutations.